Inhibitory Effects of Resveratrol on PDGF-BB-Induced Retinal Pigment Epithelial Cell Migration via PDGFRβ, PI3K/Akt and MAPK pathways

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Chan, Chi Ming ^a,b   Chang, Hsun Hsien ^c   Wang, Vin Chi ^a,b   Huang, Chuen Lin ^a,d   Hung, Chi Feng ^b,c  

^a CARDINAL TIEN HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; RESVERATROL; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL ADHESION; CELL MIGRATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; PIGMENT EPITHELIUM; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WOUND HEALING;

CELL ADHESION; CELL LINE; CELL MOVEMENT; CELL SURVIVAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; MAP KINASE SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RETINAL PIGMENT EPITHELIUM; STILBENES;

EID: 84874014461     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056819     Document Type: Article

References (64)

1. Ho J, Witkin AJ, Liu J, Chen Y, Fujimoto JG, et al. (2011) Documentation of intraretinal retinal pigment epithelium migration via high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 118: 687-693.
2. Charteris DG, Sethi CS, Lewis GP, Fisher SK, (2002) Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye (Lond) 16: 369-374.
3. Cardillo JA, Stout JT, LaBree L, Azen SP, Omphroy L, et al. (1997) Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology 104: 1166-1173.
4. Campochiaro PA, (1997) Pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol 115: 237-241.
5. de Silva DJ, Kwan A, Bunce C, Bainbridge J, (2008) Predicting visual outcome following retinectomy for retinal detachment. Br J Ophthalmol 92: 954-958.
6. Charteris DG, (1995) Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol 79: 953-960.
7. Robbins SG, Mixon RN, Wilson DJ, Hart CE, Robertson JE, et al. (1994) Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci 35: 3649-3663.
8. Marques FZ, Markus MA, Morris BJ, (2009) Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol 41: 2125-2128.
9. Kiselev KV, (2011) Perspectives for production and application of resveratrol. Appl Microbiol Biotechnol 90: 417-425.
10. Yu W, Fu YC, Wang W, (2012) Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem 113: 752-759.
11. Frombaum M, Le Clanche S, Bonnefont-Rousselot D, Borderie D, (2012) Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and *NO bioavailability: Potential benefits to cardiovascular diseases. Biochimie 94: 269-276.
12. Chen Q, Ganapathy S, Singh KP, Shankar S, Srivastava RK, (2010) Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 5: e15288.
13. Lubbers J, Lewis S, Harper E, Hledin MP, Marquez GA, et al. (2011) Resveratrol enhances anti-proliferative effect of VACM-1/cul5 in T47D cancer cells. Cell Biol Toxicol 27: 95-105.
14. Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, et al. (2010) Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 101: 488-493.
15. Wang KT, Chen LG, Tseng SH, Huang JS, Hsieh MS, et al. (2011) Anti-inflammatory effects of resveratrol and oligostilbenes from Vitis thunbergii var. taiwaniana against lipopolysaccharide-induced arthritis. J Agric Food Chem 59: 3649-3656.
16. Csiszar A, (2011) Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Ann N Y Acad Sci 1215: 117-122.
17. Szekeres T, Saiko P, Fritzer-Szekeres M, Djavan B, Jager W, (2011) Chemopreventive effects of resveratrol and resveratrol derivatives. Ann N Y Acad Sci 1215: 89-95.
18. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, et al. (2010) Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70: 7392-7399.
19. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, et al. (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70: 9003-9011.
20. Huang X, Zhu HL, (2011) Resveratrol and its analogues: promising antitumor agents. Anticancer Agents Med Chem 11: 479-490.
21. Penumathsa SV, Maulik N, (2009) Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can J Physiol Pharmacol 87: 275-286.
22. Petrovski G, Gurusamy N, Das DK, (2011) Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci 1215: 22-33.
23. Chan CM, Huang JH, Chiang HS, Wu WB, Lin HH, et al. (2010) Effects of (-)-epigallocatechin gallate on RPE cell migration and adhesion. Mol Vis 16: 586-595.
24. Chan CM, Fang JY, Lin HH, Yang CY, Hung CF, (2009) Lycopene inhibits PDGF-BB-induced retinal pigment epithelial cell migration by suppression of PI3K/Akt and MAPK pathways. Biochem Biophys Res Commun 388: 172-176.
25. Giaever I, Keese CR, (1991) Micromotion of mammalian cells measured electrically. Proc Natl Acad Sci U S A 88: 7896-7900.
26. Leavesley DI, Schwartz MA, Rosenfeld M, Cheresh DA, (1993) Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol 121: 163-170.
27. Chan CM, Huang JH, Lin HH, Chiang HS, Chen BH, et al. (2008) Protective effects of (-)-epigallocatechin gallate on UVA-induced damage in ARPE19 cells. Mol Vis 14: 2528-2534.
28. Hughes AD, Clunn GF, Refson J, Demoliou-Mason C, (1996) Platelet-derived growth factor (PDGF): actions and mechanisms in vascular smooth muscle. Gen Pharmacol 27: 1079-1089.
29. Andrae J, Gallini R, Betsholtz C, (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22: 1276-1312.
30. Betsholtz C, Karlsson L, Lindahl P, (2001) Developmental roles of platelet-derived growth factors. Bioessays 23: 494-507.
31. Heldin CH, Westermark B, (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316.
32. Rosenkranz S, Kazlauskas A, (1999) Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 16: 201-216.
33. Li X, Eriksson U, (2003) Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev 14: 91-98.
34. Pastor JC, de la Rua ER, Martin F, (2002) Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res 21: 127-144.
35. Pastor JC, (1998) Proliferative vitreoretinopathy: an overview. Surv Ophthalmol 43: 3-18.
36. Campochiaro PA, Hackett SF, Vinores SA, Freund J, Csaky C, et al. (1994) Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells. J Cell Sci 107 (Pt 9): 2459-2469.
37. Vinores SA, Henderer JD, Mahlow J, Chiu C, Derevjanik NL, et al. (1995) Isoforms of platelet-derived growth factor and its receptors in epiretinal membranes: immunolocalization to retinal pigmented epithelial cells. Exp Eye Res 60: 607-619.
38. Seo MS, Okamoto N, Vinores MA, Vinores SA, Hackett SF, et al. (2000) Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. Am J Pathol 157: 995-1005.
39. Mori K, Gehlbach P, Ando A, Dyer G, Lipinsky E, et al. (2002) Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy. Invest Ophthalmol Vis Sci 43: 2001-2006.
40. Saishin Y, Takahashi K, Seo MS, Melia M, Campochiaro PA, (2003) The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies. Invest Ophthalmol Vis Sci 44: 3656-3662.
41. Zheng Y, Ikuno Y, Ohj M, Kusaka S, Jiang R, et al. (2003) Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn J Ophthalmol 47: 158-165.
42. Ikuno Y, Leong FL, Kazlauskas A, (2000) Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor. Invest Ophthalmol Vis Sci 41: 3107-3116.
43. Ikuno Y, Kazlauskas A, (2002) An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor. Invest Ophthalmol Vis Sci 43: 2406-2411.
44. Lei H, Rheaume MA, Kazlauskas A, (2010) Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Res 90: 376-381.
45. Lei H, Rheaume MA, Velez G, Mukai S, Kazlauskas A, (2011) Expression of PDGFRalpha is a determinant of the PVR potential of ARPE19 cells. Invest Ophthalmol Vis Sci 52: 5016-5021.
46. Hiscott P, Gray R, Grierson I, Gregor Z, (1994) Cytokeratin-containing cells in proliferative diabetic retinopathy membranes. Br J Ophthalmol 78: 219-222.
47. Hamilton CW, Chandler D, Klintworth GK, Machemer R, (1982) A transmission and scanning electron microscopic study of surgically excised preretinal membrane proliferations in diabetes mellitus. Am J Ophthalmol 94: 473-488.
48. Waltman SR, Oestrich C, Krupin T, Hanish S, Ratzan S, et al. (1978) Quantitative vitreous fluorophotometry. A sensitive technique for measuring early breakdown of the blood-retinal barrier in young diabetic patients. Diabetes 27: 85-87.
49. Akiyama H, Kachi S, Silva RL, Umeda N, Hackett SF, et al. (2006) Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies. J Cell Physiol 207: 407-412.
50. Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y, (2011) Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol 55: 256-263.
51. Praidou A, Klangas I, Papakonstantinou E, Androudi S, Georgiadis N, et al. (2009) Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Curr Eye Res 34: 152-161.
52. Cao L, Liu H, Lam DS, Yam GH, Pang CP, (2010) In vitro screening for angiostatic potential of herbal chemicals. Invest Ophthalmol Vis Sci 51: 6658-6664.
53. Venkatesan B, Valente AJ, Reddy VS, Siwik DA, Chandrasekar B, (2009) Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration. Am J Physiol Heart Circ Physiol 297: H874-886.
54. Kim DS, Kwon HM, Choi JS, Kang SW, Ji GE, et al. (2007) Resveratrol blunts tumor necrosis factor-alpha-induced monocyte adhesion and transmigration. Nutr Res Pract 1: 285-290.
55. Cicha I, Regler M, Urschel K, Goppelt-Struebe M, Daniel WG, et al. (2011) Resveratrol inhibits monocytic cell chemotaxis to MCP-1 and prevents spontaneous endothelial cell migration through Rho kinase-dependent mechanism. J Atheroscler Thromb 18: 1031-1042.
56. Tang FY, Su YC, Chen NC, Hsieh HS, Chen KS, (2008) Resveratrol inhibits migration and invasion of human breast-cancer cells. Mol Nutr Food Res 52: 683-691.
57. Lee MF, Pan MH, Chiou YS, Cheng AC, Huang H, (2011) Resveratrol modulates MED28 (Magicin/EG-1) expression and inhibits epidermal growth factor (EGF)-induced migration in MDA-MB-231 human breast cancer cells. J Agric Food Chem 59: 11853-11861.
58. Ong ET, Hwang TL, Huang YL, Lin CF, Wu WB, (2011) Vitisin B, a resveratrol tetramer, inhibits migration through inhibition of PDGF signaling and enhancement of cell adhesiveness in cultured vascular smooth muscle cells. Toxicol Appl Pharmacol 256: 198-208.
59. Scheiffarth OF, Kampik A, Gunther H, von der Mark K, (1988) Proteins of the extracellular matrix in vitreoretinal membranes. Graefes Arch Clin Exp Ophthalmol 226: 357-361.
60. Hinton DR, He S, Graf K, Yang D, Hsueh WA, et al. (1998) Mitogen-activated protein kinase activation mediates PDGF-directed migration of RPE cells. Exp Cell Res 239: 11-15.
61. Smith-Thomas L, Richardson P, Parsons MA, Rennie IG, Benson M, et al. (1996) Additive effects of extra cellular matrix proteins and platelet derived mitogens on human retinal pigment epithelial cell proliferation and contraction. Curr Eye Res 15: 739-748.
62. Haugland HK, Tysnes BB, Tysnes OB, (1997) Adhesion and migration of human glioma cells are differently dependent on extracellular matrix molecules. Anticancer Res 17: 1035-1042.
63. Wagner M, Benson MT, Rennie IG, MacNeil S, (1995) Effects of pharmacological modulation of intracellular signalling systems on retinal pigment epithelial cell attachment to extracellular matrix proteins. Curr Eye Res 14: 373-384.
64. Powell RJ, Carruth JA, Basson MD, Bloodgood R, Sumpio BE, (1996) Matrix-specific effect of endothelial control of smooth muscle cell migration. J Vasc Surg 24: 51-57.